Yu Gui1, Shuman Xu1, Xi Yang1, Lu Gu2,3, Ze Zhang2,3, Xiangdong Luo2,3, Li Chen1,3. 1. Breast Disease Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. 2. Burn Research Institute, Southwest Hospital, Third Military Medical University, Chongqing 400038, China. 3. National Key Laboratory of Trauma & Burns, Chongqing Key Lab. of Disease Proteomics, Chongqing, China.
Abstract
UNLABELLED: Identification of biomarkers that has the ability to predict triple-negative breast cancer (TNBC) prognosis especially in patients undergoing chemotherapy is very important. METHODS: The cohort studies that reported association between chemotherapy biomarker expression and survival outcome in TNBC patients were included in our analysis. RESULTS: The promising markers that emerged for the prediction of disease-free survival and overall survival included Ki67, BRCA1 methylation and LC3B. Furthermore, Ki67 appeared to be also significantly associated with worse disease-free survival in TNBC patients who received anthracycline-based chemotherapy. CONCLUSION: This meta-analysis demonstrated that in TNBC patients receiving chemotherapy, Ki67 is a predictor for poor prognosis, BRCA1 methylation and LC3B are also potential prognostic markers. In addition, the TNBC patients with high Ki67 expression seems to display resistance to anthracycline-based chemotherapy.
UNLABELLED: Identification of biomarkers that has the ability to predict triple-negative breast cancer (TNBC) prognosis especially in patients undergoing chemotherapy is very important. METHODS: The cohort studies that reported association between chemotherapy biomarker expression and survival outcome in TNBC patients were included in our analysis. RESULTS: The promising markers that emerged for the prediction of disease-free survival and overall survival included Ki67, BRCA1 methylation and LC3B. Furthermore, Ki67 appeared to be also significantly associated with worse disease-free survival in TNBC patients who received anthracycline-based chemotherapy. CONCLUSION: This meta-analysis demonstrated that in TNBC patients receiving chemotherapy, Ki67 is a predictor for poor prognosis, BRCA1 methylation and LC3B are also potential prognostic markers. In addition, the TNBC patients with high Ki67 expression seems to display resistance to anthracycline-based chemotherapy.
Entities:
Keywords:
biomarkers; chemotherapy; meta-analysis; prognosis; triple-negative breast cancer